Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proline dapagliflozin plus tadalafil for overweight or obese men with type 2 diabetes mellitus and erectile dysfunction
ChiCTR2600135609Phase 4Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in erectile dysfunction (ED), type 2 diabetes mellitus (T2DM), Overweight and 1 more comparing Dapagliflozin proline tablets plus tadalafil with Placebo plus tadalafil (2 arms). Primary endpoint: International Index of Erectile Function-Erectile Function Domain score. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozintadalafil
03
Conditions
erectile dysfunction (ED)type 2 diabetes mellitus (T2DM)Overweightobesity
Beyond the preview
Go deeper on ChiCTR2600135609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135609.